RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Omaveloxolone Lotion 0.5%|DRUG: Omaveloxolone Lotion 3%|DRUG: Vehicle Lotion|RADIATION: 3D conformal radiation therapy
Sponsor: Reata, a wholly owned subsidiary of Biogen
Collaborators: AbbVie